Palovarotene

Drug Profile

Palovarotene

Alternative Names: Clm-001; R-667; RG-667; RO-3300074

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Clementia Pharmaceuticals; Roche
  • Class Benzoic acids; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibrodysplasia ossificans progressiva
  • Discontinued Emphysema

Most Recent Events

  • 14 Nov 2016 Clementia Pharmaceuticals suspends enrolment in a phase II trial for Fibrodysplasia ossificans progressiva in USA (NCT02521792)
  • 01 Nov 2016 Clementia Pharmaceuticals initiates an extension phase II trial for Fibrodysplasia ossificans progressiva (In adolescents, In adults, In children) in France (PO) (NCT02979769)
  • 14 Oct 2016 Positive top-line efficacy and adverse events data from a phase II trial in Fibrodysplasia ossificans progressiva (In children, In adolescents, In adults) released by Clementia Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top